Lactobacillus plantarum CCFM1143 effectively mitigates intestinal inflammatory responses and alleviates chronic diarrhea by suppressing the elevation of pro-inflammatory cytokines such as Interleukin-6 (IL-6), while simultaneously modulating the levels of short-chain fatty acids (SCFAs) in the gut, including acetate and propionate. This dual intervention mechanism, combining anti-inflammatory action with microecological regulation, has been shown to significantly improve bowel movement frequency and stool consistency. Furthermore, its efficacy for chronic and infectious diarrhea is supported by rigorous double-blind, randomized, placebo-controlled clinical trials, providing a reliable solution for gut health management.
This outstanding clinical efficacy is underpinned by the high-dose advantages of this potent probiotic and top-tier formulation technology. To ensure that high-dose CCFM1143 accurately and safely reaches its intestinal targets, the product utilizes advanced VPro-5 layer encapsulation technology. This five-tier protective barrier endows the strain with exceptional stress resistance, ensuring that the probiotics maintain high viability and long-term stability throughout complex transportation and storage processes. Consequently, a sufficient number of viable cells can reach the intestines to exert their anti-inflammatory and microbiota-modulating effects.
Backed by robust evidence-based medicine, CCFM1143 demonstrates comprehensive scientific validation. Clinical research confirms that this strain not only alleviates symptoms of chronic diarrhea but also specifically intervenes in gut dysbiosis caused by infections such as Enterotoxigenic Escherichia coli (ETEC). For companies dedicated to developing next-generation precision nutrition products, selecting CCFM1143 means choosing a premier multifunctional ingredient that combines cutting-edge scientific mechanisms, ultra-high viable cell potency, and comprehensive global compliance.